COLYM Program

Friday, October 6, 2023
09:15-10:45 Session 1: What’s new in the field of lymphomas? Keynote lectures
09:15-09:35 Staging and response assessment criteria in lymphomas. Update from ICML: TBA
Bringing genomics to the clinic in DLBCL:
09:35-09:50 The pathologist point of view: Miguel Angel Piris, Spain
09:50-10:05 The clinician point of view: Andrew Davies, UK
10:05-10:25 Artificial intelligence in the diagnosis and staging of lymphomas: TBA
10:25-10:45 Roundtable discussion: All session faculty
10:45-11:15 Coffee Break
11:15-12:45 Session 2: CLL and Richter’s syndrome
11:15-11:35 Front line therapy in CLL: Time limited vs continuous: Farrukh Awan, USA
11:35-11:55 High risk CLL in the ear of BTKi and BCL2 inhibitors: Is allo-HCT still a valid option? Mohamed Kharfan-Dabaja, USA
Best therapeutic option of Richter’s syndrome is:
11:55-12:05 Novel agents: Farrukh Awan, USA
12:05-12:15 Allo-HCT: Alex Herrera, USA
12:15-12:25 CAR T cells: Sairah Ahmed, USA
12:25-12:45 Roundtable discussion: All session faculty
12:45-13:00 Lunch Box pick-up and Break
13:00-14:30 Industry symposium timeslot
14:30-14:45 Technical Break
14:45-16:15 Session 3: Follicular lymphoma
Best option for treatment naïve FL patients is:
14:45-15:00 Chemo free strategies: Julio Chavez, USA
15:00-15:15 R-chemo strategies: TBA
Sequencing treatment in RR FL patients:
15:15-15:30 Bispecific MoAb before CAR T cells are the SOC: Alex Herrera, USA
15:30-15:45 CAR T cells before bispecific MoAb are the SOC: Mazyar Shadman, USA
15:45-16:15 Roundtable discussion: All session faculty
16:15-16:45 Coffee Break
16:45-18:15 Session 4: Diffuse large B cell lymphomas
Is R-CHOP still the SOC for first line therapy in DLBCL?
16:45-17:00 Yes: Marek Trněný, Czech Republic
17:00-17:15 No: Hervé Tilly, France
Most feasible option for 3L therapy in DLBCL patients:
17:15-17:30 CD19 autologous CAR T cells: Anna Sureda, Spain
17:30-17:45 CD19.20 autologous CAR T cells: TBA
17:45-18:00 CD20-CD3 bispecific monoclonal antibodies: Elly Lugtenburg, Netherlands
18:00-18:15 Roundtable discussion: All session faculty
Saturday, October 7, 2023
09:15-10:45 Session 5: Peripheral T cell lymphomas 
09:15-09:30 Insights in molecular pathology of PTCL: Laurence de Leval, Switzerland
PTCL NOS in CR1:
09:30-09:45 SOC is watchful waiting: TBA
09:45-10:00 SOC is auto-HCT: Graham Collins, UK
RR T cell NHL:
10:00-10:15 Novel agents in R/R T cell lymphomas: Christopher Fox, UK
10:15-10:30 Allogeneic transplant in R/R T cell lymphomas: Mehdi Hamadani, USA
10:30-10:45 Roundtable discussion: All session faculty
10:45-11:15 Coffee Break
11:15-12:45 Session 6: Hodgkin’s lymhoma
11:15-11:35 The role of radiotherapy in 2023: Lena Specht, Denmark
11:35-11:50 What is the role for response-adapted first line treatment strategies? Andrea Gallamini, France
11:50-12:10 Is HDT and autoHCT still SOC in the era of novel therapies? Ali Bazarbachi, Lebanon
12:10-12:30 When do I consider allogeneic HCT in cHL previously treated with BV and CKI? Miguel Perales, USA
12:30-12:45 Roundtable discussion: All session faculty
12:45-13:00 Lunch Box pick-up and Break
13:00-14:30 Industry symposium timeslot
14:30-14:45 Technical Break
14:45-16:15 Session 7: Mantle cell lymphoma
Front line consolidation with high-dose therapy and auto-HCT and post-transplant R maintenance: Should this approach be adandoned?
14:45-15:00 Yes: TBA
15:00-15:15 No: TBA
Best therapy for RR MCL is:
15:15-15:30 Cellular therapy: Alejandro Martín García-Sancho, Spain
15:30-15:45 BTKs: Wojciech Jurczak, Poland
15:45-16:15 Roundtable discussion: All session faculty

Registration

Register for the Joint IACH Meeting 2023